Moxifloxacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Moxifloxacin: From Antibacterial Use to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Moxifloxacin is a fluoroquinolone antibiotic that is marketed in the United States in oral and injectable forms. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Moxifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV. Its established use is against bacterial infections.
Polyclonal hyperviscosity syndrome is a protein-driven rheological problem, not a bacterial infection. No plausible mechanistic link between the two was identified. The very high TxGNN score (99.98%) reflects a graph-based association only. No clinical or literature evidence supports it, so the prediction should be treated as a hypothesis with no mechanistic backing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA202632 | Moxifloxacin Hydrochloride | Tablet, film coated | Bryant Ranch Prepack |
| ANDA212616 | Moxifloxacin Hydrochloride | Solution | Upsher-Smith Laboratories, LLC |
| ANDA202632 | Moxifloxacin Hydrochloride | Tablet, film coated | A-S Medication Solutions |
| NDA205572 | Moxifloxacin | Injection, solution | Hp Halden Pharma AS |
Routes of administration on the market: oral, injectable, and other (solution/drops).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based score. It has no clinical trials, no literature, and no plausible mechanism linking an antibacterial to a hyperviscosity condition. The evidence level is L5.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank, and a testable mechanistic hypothesis for hyperviscosity
- Any clinical or preclinical study on moxifloxacin in this condition; none was retrieved
- The same evidence pack ranks bubonic plague as the only prediction with a research-question status (S1, L4, preclinical evidence only). It would be a more productive candidate for follow-up, and its label status should be checked first.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.